Drug intelligence / Profile preview

Tawon Liar

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Tawon Liar is a product marketed as an "all-natural" herbal supplement for pain, rheumatism, insomnia, immune support, increased energy, and lowering cholesterol. FDA analysis has determined that it contains three undeclared pharmaceutical ingredients: meloxicam (a non-steroidal anti-inflammatory drug, NSAID), ketorolac (an NSAID), and dexamethasone (a corticosteroid). Meloxicam and ketorolac exert anti-inflammatory effects by inhibiting prostaglandin synthesis through cyclooxygenase (COX) enzyme inhibition. Dexamethasone acts as a glucocorticoid agonist, suppressing multiple inflammatory pathways. The inclusion of these pharmaceuticals in an unregulated supplement poses significant health risks, including increased risk for cardiovascular events, gastrointestinal bleeding, adrenal suppression, impaired immune response, hyperglycemia, and adverse drug interactions. These risks are heightened because the ingredients are undisclosed and use is unsupervised, potentially leading to severe adverse events and drug-induced conditions such as vasculitis and adrenal insufficiency[1][2][3][5][6][8].

Brand names
Tawon Liar
02

Targets

GR (Glucocorticoid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Tawon Liar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tawon Liar.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call